CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,765 | -19.1% | 127 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $7,130 | +24.1% | 127 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $5,744 | +11.3% | 127 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $5,163 | -35.5% | 127 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $8,000 | 0.0% | 127 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $8,000 | 0.0% | 127 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $8,000 | -77.1% | 127 | -72.3% | 0.00% | -75.0% |
| Q4 2021 | $35,000 | -34.0% | 458 | -3.4% | 0.00% | -42.9% |
| Q3 2021 | $53,000 | -31.2% | 474 | 0.0% | 0.01% | -36.4% |
| Q2 2021 | $77,000 | -99.5% | 474 | +273.2% | 0.01% | +266.7% |
| Q1 2021 | $15,475,000 | – | 127 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |